Relaxin immunoglobulin fusion proteins and methods of use
US11161891B2 · kind B2 · utility
1Cited by
18References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2016 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Dec 30, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.